Tirzepatide
approvedAlso known as: Mounjaro, Zepbound, LY3298176
**Mechanism of Action** Tirzepatide is a synthetic peptide that functions as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This unique co-agonism enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, delays gastric emptying, and promotes satiety. The GIP component is thought to amplify the GLP-1-mediated effects, leading to superior glycemic control and weight reduction compared to selective GLP-1 receptor agonists. **Key Research Findings** Clinical trials (e.g., SURPASS and SURMOUNT programs) demonstrate that tirzepatide significantly reduces HbA1c (up to 2.1–2.4% from baseline) and body weight (up to 15–22% in obesity cohorts) in a dose-dependent manner. Mechanistic studies show enhanced beta-cell function, improved insulin sensitivity, and favorable lipid profiles. Adverse effects are primarily gastrointestinal (nausea, vomiting, diarrhea), with a low risk of hypoglycemia when used without insulin secretagogues. **Clinical Relevance** Approved by the FDA (2022) for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), tirzepatide represents a first-in-class dual incretin therapy. Its efficacy in reducing cardiovascular risk markers and potential benefits in non-alcoholic steatohepatitis (NASH) are under investigation. Long-term safety data continue to accumulate, with ongoing studies evaluating cardiovascular outcomes. For research purposes only — not medical advice.
Key data
C225H348N48O68Research & studies
Tirzepatide led to a mean weight reduction of 20.2% vs. 13.7% with semaglutide at 72 weeks.; Waist circumference decreased by 18.4 cm with tirzepatide vs. 13.0 cm with semaglutide.; More participants on tirzepatide achieved weight reductions of at least 10%, 15%, 20%, and 25%.; Gastrointestinal adverse events were common in both groups, mostly mild to moderate during dose escalation.
Tirzepatide is approved at 5, 10, and 15 mg doses for both type 2 diabetes and chronic weight management.; The SURMOUNT program demonstrates tirzepatide enables many patients to achieve 20% weight loss.; Tirzepatide improves multiple obesity-related complications including sleep apnea, MASH, heart failure with preserved ejection fraction, and diabetes prevention.; Ongoing trials will assess long-term safety, efficacy including cardiovascular outcomes, and cost-effectiveness.
Tirzepatide users had significantly higher likelihood of achieving 5%, 10%, and 15% weight loss than semaglutide users.; On-treatment weight loss was greater with tirzepatide at 3 months (difference -2.4%), 6 months (-4.3%), and 12 months (-6.9%).; Gastrointestinal adverse event rates were similar between the two groups.; The study included 18,386 matched patients, with a mean baseline weight of 110 kg and 52% having type 2 diabetes.
MASH resolution without fibrosis worsening occurred in 62% of the 15-mg tirzepatide group vs. 10% in placebo (difference 53 percentage points, P<0.001).; Fibrosis improvement by at least one stage without MASH worsening was seen in 55% of the 5-mg group vs. 30% in placebo (difference 25 percentage points).; Gastrointestinal adverse events were the most common side effects with tirzepatide, mostly mild or moderate in severity.; Larger and longer trials are needed to confirm efficacy and safety for MASH treatment.
Mean weight change from week 36 to 88 was -5.5% with tirzepatide vs +14.0% with placebo (difference -19.4%, P < .001).; 89.5% of tirzepatide-treated participants maintained ≥80% of lead-in weight loss at week 88 vs 16.6% with placebo (P < .001).; Overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide and 9.9% for placebo.; Most common adverse events were mild to moderate gastrointestinal events, more frequent with tirzepatide.
Tirzepatide is being compared to dulaglutide for cardiovascular safety and efficacy in type 2 diabetes patients with established atherosclerotic disease.; The primary endpoint is time to first MACE (cardiovascular death, myocardial infarction, or stroke), with noninferiority margin of 1.05.; 13,299 participants were randomized across 30 countries, with mean HbA1c 8.4% and BMI 32.6 kg/m².; 65.0% had coronary disease, 19.1% prior stroke, and 25.3% peripheral artery disease at baseline.
Frequently asked questions
What is Tirzepatide?
**Mechanism of Action** Tirzepatide is a synthetic peptide that functions as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This unique co-agonism enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, delays gastri
How does Tirzepatide work?
Dual GIP/GLP-1 receptor agonist delivering potent glucose lowering and weight reduction.
What is the research status of Tirzepatide?
Tirzepatide is currently classified as approved, with 2,273 research references on record. This is for research purposes only and is not medical advice.
What is the half-life of Tirzepatide?
The reported half-life of Tirzepatide is ~5 days.
What is the molecular weight of Tirzepatide?
Tirzepatide has a molecular weight of approximately 4813 g/mol (formula C225H348N48O68).
Related peptides
Once-daily acylated GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
Long-acting GLP-1 receptor agonist that improves glycemic control, slows gastric emptying, and reduces appetite.
Exendin-4-based GLP-1 receptor agonist from Gila monster venom; first-in-class incretin mimetic.
Once-weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment for extended half-life.
Short-acting exendin-4-based GLP-1 receptor agonist with pronounced gastric-emptying delay.
Amylin analog adjunct to insulin that slows gastric emptying, suppresses glucagon, and increases satiety.
Build on Tirzepatide data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key